Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis.
Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents have changed the therapeutic approach to this disease. Interferon beta (IFNbeta)-1b represents the pioneer of those therapies. There is growing evidence from clinical trials on relapsing-remitting MS and clinically isolated syndromes suggestive of MS that IFNbeta-1b reduces the frequency and severity of relapses and the development of new and active brain lesions as assessed by magnetic resonance imaging. Long-term data suggest a persistent efficacy of IFNbeta-1b on disease activity and a positive effect in slowing disability worsening. Furthermore a reduction of relapse rate and a slight positive effect on the progression were demonstrated when IFNbeta-1b was administered to still-active secondary progressive MS. IFNbeta-1b therapy is well tolerated and relatively free of long-term side effects. In spite of the emergence of new agents for the treatment of MS, IFNbeta-1b still remains a first-line therapy with a fundamental role in all stages of the disease.
Paolicelli
Damiano
D
Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy.
Direnzo
Vita
V
Trojano
Maria
M
J Exp Med. 1995 Nov 1;182(5):1517-25
7595221
Clin Neurol Neurosurg. 2004 Jun;106(3):255-8
15177779
Ann Neurol. 1997 May;41(5):669-74
9153530
Ann Neurol. 1996 Dec;40(6):853-63
9007090
J Neuroimmunol. 1996 Jul;67(2):111-8
8765333
J Interferon Res. 1993 Oct;13(5):333-40
8301153
J Neurol. 2005 Sep;252 Suppl 3:iii44-iii50
16170501
Proc Natl Acad Sci U S A. 1984 Sep;81(18):5662-6
6091102
J Neurol Sci. 2009 Feb 1;277 Suppl 1:S19-24
19200860
Neurology. 2003 Jan 14;60(1):37-43
12525715
Ann Neurol. 1983 Mar;13(3):227-31
6847134
Ann Neurol. 1990 Feb;27(2):207-10
2138445
Neurology. 2008 Mar 25;70(13 Pt 2):1119-27
18272865
Neurology. 1999 Apr 12;52(6):1277-9
10214759
Drug Saf. 2000 Feb;22(2):149-59
10672896
Neurology. 1993 Apr;43(4):655-61
8469318
Pharm Res. 1993 Apr;10(4):567-72
8483840
Clin Pharmacokinet. 1990 Nov;19(5):390-9
1702693
Neurology. 2005 Jul 12;65(1):40-7
16009883
Arch Neurol. 2007 Sep;64(9):1292-8
17846268
Neurology. 2006 Apr 11;66(7):1056-60
16510769
Neurology. 2001 Dec 11;57(11):1969-75
11739811
Ann Neurol. 2005 Dec;58(6):840-6
16283615
Lancet. 2001 May 19;357(9268):1576-82
11377645
Neurology. 2006 Oct 10;67(7):1242-9
16914693
N Engl J Med. 1998 Jan 29;338(5):278-85
9445407
Neurology. 1999 Nov 10;53(8):1622-7
10563602
Neurology. 1998 May;50(5):1294-300
9595977
Arch Neurol. 2001 Jan;58(1):65-70
11176938
Ann Neurol. 2004 Apr;55(4):458-68
15048884
Lancet. 1998 Nov 7;352(9139):1491-7
9820296
J Neurol Neurosurg Psychiatry. 2008 Jun;79(6):646-51
17986500
J Int Med Res. 2007 Mar-Apr;35(2):173-87
17542405
Neurology. 1996 Oct;47(4):889-94
8857714
J Neurol. 2008 Apr;255(4):480-7
18004635
Lancet. 2007 Aug 4;370(9585):389-97
17679016
Neurology. 1995 Jul;45(7):1277-85
7617182
Neurology. 1993 Apr;43(4):662-7
8469319
Brain. 2002 Oct;125(Pt 10):2202-12
12244078
Lancet. 2002 Apr 27;359(9316):1453-60
11988242
J Neuroimmunol. 1993 Jul;46(1-2):145-53
8360326
Ann Neurol. 2007 Apr;61(4):300-6
17444502
Lancet. 2003 Oct 11;362(9391):1184-91
14568740
Mult Scler. 2004 Apr;10(2):126-38
15124756
N Engl J Med. 2000 Sep 28;343(13):898-904
11006365
Neurology. 2004 Mar 9;62(5):719-25
15007120
Ann Neurol. 1996 Dec;40(6):846-52
9007089